Brad Schuller, PhD, DABR is a board-certified therapeutic medical physicist specializing in radiopharmaceutical dosimetry, radiobiology, and clinical development strategy. He received his PhD in Radiation Biophysics from the Department of Nuclear Science and Engineering at the Massachusetts Institute of Technology (MIT) and brings nearly 20 years of experience in radiation science, spanning clinical, academic, and industry settings.

Most recently, Dr. Schuller served as Head of Medical Physics at a clinical-stage radiopharmaceutical company, where he led dosimetry and radiobiology strategy for pre-clinical and first-in-human programs and was instrumental in regulatory direction and submissions, including the development of critical administered activity arguments enabling a successful IND submission and the initiation of an actinium-225-based clinical trial. He is certified by the American Board of Radiology (ABR) in therapeutic medical physics.

Dr. Schuller provides independent scientific advisory services to radiopharmaceutical companies, investors, and clinical groups, with a focus on translating complex dosimetry and radiobiology concepts into actionable development decisions.

Areas of Expertise

Scientific Advisory in Radiopharmaceutical Development

  • Independent guidance on dosimetry and radiobiology strategy across pre-clinical and clinical programs

  • Interpretation of dose modeling and imaging data to inform development decisions

  • Dosimetry support for clinical and pre-clinical programs: kinetic modeling & curve fitting, TIAC calculations, absorbed dose calculations, daughter redistribution modeling, therapeutic index calculations, human translation

Investor and Scientific Diligence

  • Technical due diligence for investors evaluating radiopharmaceutical platforms and programs

  • Assessment of dose modeling, biological plausibility, and development strategy

Clinical Development and Dose Strategy

  • Advisory support for dose selection, escalation strategies, and treatment paradigms

  • Integration of imaging, pharmacokinetics, and biological response into clinical planning

Regulatory and Translational Science

  • Scientific input for IND-enabling work and regulatory materials

  • Guidance on modeling assumptions, dose-response relationships, and radiobiology frameworks

Independent Review and Technical Oversight

  • Evaluation of internal and CRO-generated dosimetry and imaging analyses

  • Identification of key risks, assumptions, and opportunities within datasets

Scientific Communication and Publications

  • Support for manuscripts, conference materials, and scientific messaging

  • Translation of complex technical concepts into clear, decision-relevant insights

Selected Publications

Radiopharmaceutical Development

  • Glantschnig, L., Enke, J. S., Schuller, B. W., Fenn, E. J., Dierks, A., Patt, M., ... & Lapa, C. (2026). Initial Clinical Experience with [177Lu] Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and Dosimetry. Journal of Nuclear Medicine.

  • Enke, J. S., Schuller, B. W., Glantschnig, L., Kircher, M., Bundschuh, R. A., Dierks, A., ... & Lapa, C. (2025). Biodistribution and radiation dosimetry for [68Ga] Ga-LNTH-1363S, a probe targeting fibroblast activation protein α. Journal of Nuclear Medicine, 66(8), 1284-1290.

  • Hesterman, J., Schuller, B. W., Orcutt, K., Babich, J., Hoppin, J. (2025). Mathematical evaluation of therapeutic index as a function of radionuclide half-life in radiopharmaceutical therapy. European Association of Nuclear Medicine, EP-1135.

Precision Radiation Biology

  • Schuller, B. W., Rogers, A. B., Cormier, K. S., Riley, K. J., Binns, P. J., Julius, R., ... & Coderre, J. A. (2007). No significant endothelial apoptosis in the radiation-induced gastrointestinal syndrome. International Journal of Radiation Oncology* Biology* Physics, 68(1), 205-210.

  • Schuller, B. W., Binns, P. J., Riley, K. J., Ma, L., Hawthorne, M. F., & Coderre, J. A. (2006). Selective irradiation of the vascular endothelium has no effect on the survival of murine intestinal crypt stem cells. Proceedings of the National Academy of Sciences, 103(10), 3787-3792.

Risk Management

  • Schuller, B. W., Burns, A., Ceilley, E. A., King, A., LeTourneau, J., Markovic, A., ... & Albert, J. M. (2017). Failure mode and effects analysis: A community practice perspective. Journal of applied clinical medical physics, 18(6), 258-267.

Clinical Navigation

  • Schuller, B. W., Burch, C., Casterton, T., Crowther, C., Fowler, J., & Stenmark, M. H. (2022). Precision patient education using a “flipped classroom” approach. Journal of Applied Clinical Medical Physics, 23(5), e13601.

  • Schuller, B. W., Baldwin, J. A., Ceilley, E. A., Markovic, A., & Albert, J. M. (2020). Development of a novel medical physics patient consult program. medRxiv, 2020-06.

  • Schuller, B. W., Hendrickson, K. R., & Rong, Y. (2018). Medical physicists should meet with patients as part of the initial consult. Journal of applied clinical medical physics, 19(2), 6.